Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma

NCT04613557 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapse/Refractory Multiple Myeloma

Interventions

BIOLOGICAL: CYAD-211
DRUG: Endoxan
DRUG: Fludara

Sponsor

Celyad Oncology SA